RxSight, Inc. (NASDAQ:RXST) Insider Ilya Goldshleger Sells 3,100 Shares of Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of RxSight stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $50.19, for a total value of $155,589.00. Following the completion of the transaction, the insider now owns 42,246 shares of the company’s stock, valued at approximately $2,120,326.74. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Ilya Goldshleger also recently made the following trade(s):

• On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total value of $155,279.00.
• On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.26, for a total transaction of $149,606.00.
• On Friday, October 4th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.01, for a total transaction of $148,831.00.
• On Monday, September 30th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.02, for a total transaction of $151,962.00.
• On Thursday, September 26th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $49.29, for a total value of $153,045.45.
• On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $52.67, for a total value of $163,277.00.
• On Friday, September 20th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $53.19, for a total value of $164,889.00.
• On Monday, August 5th, Ilya Goldshleger sold 9,000 shares of RxSight stock. The stock was sold at an average price of $39.25, for a total value of $353,250.00.

RxSight Price Performance

Shares of RXST stock opened at $49.61 on Wednesday. The stock’s fifty day moving average price is $52.03 and its 200 day moving average price is $53.87. RxSight, Inc. has a 1-year low of $20.66 and a 1-year high of $66.54. The company has a market cap of $1.83 billion, a price-to-earnings ratio of -39.37 and a beta of 1.20.

RxSight (NASDAQ:RXST) last posted its quarterly earnings data on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.06. The firm had revenue of $34.89 million for the quarter, compared to the consensus estimate of $32.33 million. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. The company’s revenue for the quarter was up 67.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.40) earnings per share. As a group, equities research analysts anticipate that RxSight, Inc. will post -0.81 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in RXST. Amalgamated Bank increased its position in shares of RxSight by 21.3% in the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock valued at $71,000 after acquiring an additional 207 shares during the period. Crossmark Global Holdings Inc. raised its stake in shares of RxSight by 3.2% in the second quarter. Crossmark Global Holdings Inc. now owns 7,861 shares of the company’s stock worth $473,000 after purchasing an additional 242 shares during the last quarter. RiverPark Advisors LLC lifted its holdings in shares of RxSight by 9.6% during the second quarter. RiverPark Advisors LLC now owns 3,379 shares of the company’s stock worth $203,000 after purchasing an additional 297 shares during the period. CWM LLC boosted its position in RxSight by 727.5% in the second quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after buying an additional 371 shares during the last quarter. Finally, Arizona State Retirement System increased its holdings in RxSight by 5.0% in the 2nd quarter. Arizona State Retirement System now owns 7,765 shares of the company’s stock worth $467,000 after buying an additional 373 shares during the period. Hedge funds and other institutional investors own 78.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on RXST. Oppenheimer reduced their price target on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. BTIG Research lifted their target price on RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, July 15th. Stifel Nicolaus dropped their price target on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and issued a $66.00 price objective on shares of RxSight in a report on Friday, September 13th. Finally, Wells Fargo & Company dropped their target price on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $60.14.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.